Understanding and treating vascular cognitive impairment

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 2, 2013, Pages 425-437

  Gorelick, Philip B ^a   Nyenhuis, David ^b  

^a Saint Mary's Health Care   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLINESTERASE INHIBITOR; MEMANTINE; NIMODIPINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; HUMAN; INCIDENCE; MORTALITY; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; VASCULAR AMYLOIDOSIS; VASCULAR COGNITIVE IMPAIRMENT;

AGED; BRAIN; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; VASCULAR DISEASES;

EID: 84876354074     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000429174.29601.de     Document Type: Review

References (50)

1. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42(2):2672-2713.
2. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43(2):250-260.
3. Hachinski V. Stroke and Alzheimer disease. fellow travelers or partners in crime? Arch Neurol 2011;68(6):797-798.
4. Hachinski V. World Stroke Day 2008. "Little strokes, big trouble". Stroke 2008;39(9): 2407-2408.
5. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 suppl 5):S10-S15.
6. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999;53(9):1992-1997.
7. Ivan CS, Seshardri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke 2004;35(6):1264-1269.
8. Zhang Z-X, Zahner GEP, Roman GC, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol 2005;62(3):447-453.
9. Yamada M, Mimori Y, Kasagi F, et al. Incidence of dementia, Alzheimer disease, and vascular dementia in a Japanese population: Radiation Effects Research Foundation adult health study. Neuroepidemiology 2008;30(3):152-160.
10. Honig LS, Tang M-X, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60(12):1707-1712.
11. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64(5): 834-841.
12. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69(24):2107-2204.
13. Mitchell SL, Teno JM, Keily DK, et al. The clinical course of advanced dementia. N Engl J Med 2009;361(16):1529-1538.
14. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304(16):1787-1794.
15. Freels S, Nyenhuis D, Gorelick PB. Predictors of survival in African American patients with AD, VaD, or stroke without dementia. Neurology 2002;59(8):1146-1153.
16. Gorelick PB, Brody J, Cohen D, et al. Risk factors for dementia associated with multiple cerebral infarcts. A case-controlled analysis in predominantly African-American hospital-based patients. Arch Neurol 1993; 50(7):714-720.
17. Gorelick PB, Freels S, Harris Y, et al. Epidemiology of vascular and Alzheimer's dementia among African Americans in Chicago, IL: baseline frequency and comparison of risk factors. Neurology 1994; 44(8):1391-1396.
18. Pytel P, Cochran EJ, Bonner G, et al. Vascular and Alzheimer-type pathology in an autopsy study of African-Americans. Neurology 2006;66(3):433-435.
19. Gorelick PB. Cerebral microbleeds: evidence of heightened risk associated with aspirin use. Arch Neurol 2009;66(6):691-693.
20. Gorelick PB, William M. Feinberg Lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 2005;36(4):875-879.
21. Grysiewicz R, Gorelick PB. Update on amyloid-associated intracerebral hemorrhage. Eur Neurol Rev 2012;7:22-24.
22. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9(7):689-701.
23. Stebbins GT, Nyenhuis DL, Wang C, et al. Gray matter atrophy in patients with ischemic stroke with cognitive impairment. Stroke 2008;39(3):785-793.
24. Wang C, Stebbins GT, Nyenhuis DL. Longitudinal changes in white matter following ischemic stroke: a three-year follow-up study. Neurobiol Aging 2006;27(12):1827-1833.
25. Wu W, Brickman AM, Luchsinger J, et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 2008;64(6): 698-706.
26. Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol 2011;70(5): 774-780.
27. Nyenhuis DL, Gorelick PB, Geenen EJ, et al. The pattern of neuropsychological deficits in Vascular Cognitive Impairment-No Dementia (Vascular CIND). Clin Neuropsychol 2004; 18(1):41-49.
28. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 2012; 33(5):1006.e25-e36.
29. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37(9): 2220-2241.
30. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36(6):1330-1340.
31. Bella R, Pennisi G, Cantone M, et al. Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease. Gerontology 2010;56(3):298-302.
32. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized placebo-controlled trial. Stroke 2003;34(10):2323- 2332.
33. Orgogozo J-M, Rigaud A-S, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33(7): 1834-1839.
34. Cahn-Weiner DA, Farias ST, Julian L, et al. Cognitive and neuroimaging predictors of instrumental activities of daily living. J Int Neuropsychol Soc 2007;13(5):747-757.
35. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med 2010;153(3):176-181.
36. Pantoni L, Gorelick PB. Advances in vascular cognitive impairment 2010. Stroke 2011; 42(2):291-293
37. European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol 1996;36(6): 315-321.
38. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord 1997;8(5):320-328.
39. Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc 2006;81(10): 1350-1358.
40. Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20(6): 338-344.
41. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359(9314): 1283-1290.
42. Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007;69(5): 448-458.
43. Gorelick PB. CADASIL: do the clinical and MRI profiles differ for women and men? Stroke 2012;43(1):8-10.
44. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008;7(4):310-318.
45. Perry E, Ziabreva I, Perry R, et al. Absence of cholinergic deficits in "pure" vascular dementia. Neurology 2005;64(1):132-133.
46. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005;36(3): 619-624.
47. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293(5):596-608.
48. Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomized controlled trial. BMJ 2008;337:a1198.
49. Nelson MR, Reid C, Beilin LJ, et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003; 20(12):897-903.
50. NIH News. NIH launches multicenter clinical trial to test blood pressure strategy. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?od= 2667. Accessed November 2, 2009.